A control CDK1-selective inhibitor, bohemine, showed pronounced inhibition of proliferation of both cell types; however, the VEGFR-specific inhibitor vatalanib did not significantly inhibit cell proliferation in endothelial cells (Figure 5A) or breast cancer cells (Figure 5B). The gene discussed is CDK1; the disease is breast carcinoma.